What is Prostate Cancer Nuclear Medicine Diagnostics?
Prostate cancer is cancer that develops in the tissues of the prostate. Prostate cancer is most commonly found in elderly men. Fats promote the synthesis of testosterone and other hormones, and testosterone has been shown to hasten prostate cancer growth. High testosterone levels have been linked to the reactivation of latent prostate cancer cells. Nuclear medicine and radiology both employ radiation. Radioactive materials are known as radioisotopes, or radiopharmaceuticals, are administered into the body in nuclear medicine. X-rays enter the body from the outside in radiology. A wide range of illnesses can be diagnosed using nuclear medicine. A radiopharmaceutical will be given to the patient via inhalation, swallowing, or injection. This substance is radioactive. The patient will often lie down on a table after taking the substance while a camera captures pictures. The camera will focus on the area where the radioactive material is concentrated, allowing the doctor to see what kind of issue exists and where it is located.
The market study is broken down by Type (Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET)), by Application (Hospitals, Clinics and Others) and major geographies with country level break-up.
The nuclear medicine diagnostic market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing on the technologies and new machines implementations. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge investment in market growth strategies. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Prostate Cancer Nuclear Medicine Diagnostics market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Blue Earth Diagnostics (United Kingdom), Lantheus Medical Imagining, Inc. (United States), Theragnostics Ltd (United Kingdom), Curium Pharma (Finland), Jubilant Pharma Limited (United States), NCM-USA LLC (United States), Telix Pharmaceuticals Ltd. (Australia), Cancer Genetics, Inc. (United States), Sun Nuclear Corporation (United States) and American Pride (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are PETNET Solutions Inc. (United States), Cardinal Health (United States), ImaginAb (United States) and Novartis AG (Switzerland).
AdvanceMarketAnalytics has segmented the market of Global Prostate Cancer Nuclear Medicine Diagnostics market by Type, Application and Region.
On the basis of geography, the market of Prostate Cancer Nuclear Medicine Diagnostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by , the sub-segment i.e. will boost the Prostate Cancer Nuclear Medicine Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by PET product, the sub-segment i.e. F-18 will boost the Prostate Cancer Nuclear Medicine Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
In May 2021- GE Healthcare launched Xeleris V, a new virtual processing and review system, to give nuclear medicine professionals more freedom and time with patients. Xeleris V eliminates the need for a separate nuclear medicine workstation, allowing doctors to view data securely from several locations. This increase in access, when combined with new AI-enabled applications and GE Healthcare's vast installed base of nuclear medicine cameras, can help physicians discover, diagnose, and treat patients more accurately.
- Rising Demand for Early and Precise Diagnosis of the Disease
- Increasing research activities for the development of innovative imaging
- Rising Prevalence of Prostate Cancer
- The presence of reimbursement policies is expected to further fuel the growth of nuclear medicine diagnostics
- Adoption of PET as a diagnostic tool is significantly increasing
- Increasing demand for PET diagnostic procedures due to higher accuracy
- The high cost of the test hampers the market
- Earlier Detection of Prostate Cancer in the PSA Era
Key Target AudienceNuclear medicine Diagnostics Companies, Healthcare and Pharmaceutical Companies, Consulting and Advisory Firms, Government and Policy Makers and Regulatory Authorities
About ApproachTo evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand companys positioning regarding market value, volume and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Frequently Asked Questions (FAQ):
1. What all players are profiled in the study?
The standard version of the report profiles players such as Blue Earth Diagnostics (United Kingdom), Lantheus Medical Imagining, Inc. (United States), Theragnostics Ltd (United Kingdom), Curium Pharma (Finland), Jubilant Pharma Limited (United States), NCM-USA LLC (United States), Telix Pharmaceuticals Ltd. (Australia), Cancer Genetics, Inc. (United States), Sun Nuclear Corporation (United States) and American Pride (United States) etc.
2. Can we have customized study for Prostate Cancer Nuclear Medicine Diagnostics Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
3. What would be the Market Size of Prostate Cancer Nuclear Medicine Diagnostics Market by 2027?
Analysts at AMA estimates Prostate Cancer Nuclear Medicine Diagnostics Market to reach USD Million by 2027.